



## Regenerative Medicine

# Cellular Supplementation Technologies for Painful Spine Disorders

Michael J. DePalma, MD, Justin J. Gasper, DO

---

**Abstract**

Low back pain affects more than 80% of adults. A proportion of these adults develops chronic low back pain (CLBP) and becomes disabled by their condition. CLBP is expensive to diagnose and treat and in terms of associated loss of productivity in the work place setting by affected individuals. Although challenging, the source of CLBP can be identified. Contemporary literature contains several studies that have established prevalence estimates for various structural sources of CLBP. In young adults, the intervertebral disk is a common source of CLBP, once it incurs annular injury that heals incompletely. Effective treatment for painful disks currently is an unmet clinical need. In older adults, the facet and sacroiliac joints are more commonly responsible for CLBP. Although certain minimally invasive techniques do exist for these painful joints, an effective restorative intervention has yet to be established. Annular injury precipitates a physiologic response that can lead to a catabolic state within the disk that impairs disk restoration. Cell loss is a feature of this process as well as the pathophysiology associated with painful facet and sacroiliac joints. Cellular supplementation is an attractive treatment strategy to initiate the repair of an injured lumbosacral structure. The introduction of exogenous cells may lead to increased extracellular matrix production and reduced pain and disability in diskogenic CLBP. Compelling data in animal studies have been produced, stimulating Food and Drug Administration–regulated trials in humans. Numerous questions remain regarding cell viability and sufficient native nutrients to support these cells. Clinical research protocols have focused predominantly on diskogenic CLBP, and very few have addressed painful facet and/or sacroiliac joints.

---

**Introduction**

Chronic low back pain (CLBP) and chronic neck pain are common and expensive clinical scenarios. It has been implied, for example, that CLBP cannot be diagnosed [1-3]. Yet, certain clinical features can help predict its etiology [4,5]. Accurately determining the source of symptoms is not a futile attempt. If the exact structural source of CLBP or chronic neck pain can be identified, then perhaps a definitive treatment can be directed at the appropriate structure. Understanding how and why such a structure becomes symptomatic then becomes critical in designing a sensible treatment. Similarly, reliable and predictive metrics for rendering this diagnosis are equally important if such measures can help predict a treatment response to the said intervention.

Numerous publications have reported prevalence estimates for various structural sources of CLBP [5,6]. The intervertebral disk is a common origin of CLBP and is estimated to affect 39%-43% of symptomatic adults [5,6]. CLBP pain typically arises from nonhealing

annular fissures [5-8] and typically affects young and middle-aged adults [5]. Facet joint–mediated low back pain (LBP), followed by sacroiliac joint pain, become more prevalent in patients with CLBP who are closer to 60 years of age [5]. Clinical studies report the prevalence of facet joint pain is 32%, and sacroiliac joint pain is 18% of adults with CLBP [5,9,10].

The subspecialty of interventional spine care uses a structure-specific diagnostic approach to LBP. Such logic implies that an accurate diagnosis leads to effective treatment; however, optimal treatment for a common source of CLBP—persistently painful lumbar intervertebral disks—has not yet been developed. Spine fusion, artificial disk replacement, intradiskal heating, and intradiskal neurolytic agents have not consistently performed at acceptable levels. A reactionary approach is the common theme among these treatments rather than a reparative or regenerative concept. An alternate strategy of stimulating repair of an injured, painful disk is appealing for multiple reasons. Reducing pain and disability associated with CLBP would address more immediate needs. Yet, it is also reasonable to wonder

whether the application of a reparative technology would help slow down or reduce onset of the degenerative cascade and hence curtail conditions as the spine ages such as spinal stenosis.


Determining how and when to intervene to introduce regenerative techniques requires understanding the balance among the interdynamics of disk biology and pathophysiology. Disk degeneration is complex but could be described as a consequence of the nonhealing of an annular fissure occurring after diskogenic injury. The features of disk degeneration include reduced nutrition and metabolic byproduct removal, altered biophysical context, cell loss, changes in matrix turnover, and altered biomechanics. Biologic regenerative treatments for painful intervertebral disks presumably must address each if not all of these factors; focusing on which of these factors is perplexing and accounting for the affected individual's genetic predisposition is a relative unknown.

The scope of this article will be restricted primarily to the current state of affairs regarding the intradiskal cellular supplementation platform. Such consideration requires an overview of the pathophysiology of the condition that indicates treatment with such technologies. Cell therapy approaches have not been explored in as much detail for painful lumbar facet and sacroiliac joints because these conditions are less prevalent and currently have reasonably effective treatments available.

## Painful Intervertebral Disks

### Pathophysiology

Annular fissures [7] (Figure 1) are the morphologic substrates of diskogenic CLBP and are a distinguishing




**Figure 1.** Postdiskography computed tomography axial cut demonstrating posterior, midline radial fissure (arrow) with circumferential outer annular extension.

feature of internal disk disruption (IDD). IDD is a condition in which derangement of substructures internal to the intervertebral disk result in pain while the external contour of the disk remains relatively unremarkable. In other words, IDD is a different condition than a herniated nucleus pulposus—the latter is defined partially by the volume of the herniated material external to the disk's external contour. Age-related changes in the disk, often times referred to as degeneration, are not necessarily indicative of a clinically painful intervertebral disk [7]. The medical spine community has come to understand that advanced imaging evidence of degenerative abnormalities is not absolutely diagnostic for IDD. Therefore, the degenerative cascade itself should not serve as the sole target of biologic treatments.

Newly innervated and vascularized granulation tissue flanks these fissures that extend from the nucleus through the outer annulus [8,11-13]. In contrast, there is a paucity of innervated, vascularized granulation tissue in areas remote from these fissures within symptomatic disks and in degenerated but painless lumbar disks [8]. The innervated granulation tissue along these annular rents is a distinct histologic characteristic of IDD in patients with CLBP [8,11-13]. When performed by a technician by following stringent operational criteria, provocation lumbar diskography (Figure 2) can be used reliably to detect the annular fissures responsible for CLBP [7,14,15]. Anesthetizing these painful fissures after diskography reduces clinical LBP during provocative movements [16]. Evidence exists that supports the concept that these innervated annular fissures are a leading reason for diskogenic CLBP. Injury of the annulus catalyzes an attempt at repair typified by: inflammatory reaction [8], macrophage and mast cell invasion, and cytokine (interleukins-1, -6, and -8; tumor necrosis factor- $\alpha$ ; proteoglycan-2) and growth factor (basic fibroblast growth factor, transforming growth factor- $\beta$ ) release. These changes culminate in a disk structure with altered mechanics and impairment of chondrocyte function [8,13,17-24].

### Treatment Objectives

Either enhancing the accumulation of extracellular matrix or inhibiting its degradation theoretically reverses disk degeneration by rehydration. Specific chemical agents can be introduced into the disk by direct injection to: (1) stimulate proteoglycan production by protein growth factors or (2) inhibition of the cytokines that degrade/debase proteoglycans. A number of growth factors promote matrix accumulation, whereas certain cytokines impede matrix synthesis and accelerate its catabolism. Manipulation of gene expression, particularly transcription, rather than injecting preformed protein factors, is another method of regulating matrix turnover. Agents that protect against



**Figure 2.** Intraoperative, fluoroscopic image of disk stimulation of L4-5 and L5-S1. The vertical arrow depicts filling of the annular fissure by contrast material.

cell death or promote mitosis may hold value in disk regeneration, given the relative avascularity of the disk. Structural repair of the annular fissure may be more successful if disk degeneration is arrested and/or reversed.

Intradiskal biologic treatments for painful intervertebral disks should address the catabolic state inherent in these disks as well as counter or reverse the degenerative changes. Yet, a defining feature of successful biologic treatments will likely include healing the annular tear itself as well as the degradation initiated by the annular tear. Characteristics of painful disks such as reduced oxygen tension, acidic pH, modic endplate changes, and desiccation will influence the likelihood of any injected therapeutic agent's ability to produce positive results. For example, reduced oxygen tension and pH may reduce the longevity of an injected biologic agent. Endplate changes and disk desiccation could impede the nutrient supply needed to support newly injected biologic agents. Our current understanding of these interdynamics is still evolving. Although different intradiskal biologic strategies (growth factors, tissue

scaffolding) are being pursued, cellular supplementation is the one strategy with compelling contemporary human data.

### **Cellular Supplementation**

Cellular attrition is a consequence of degeneration, and these native cells may be less responsive to exogenous growth factors [25]. Hence, the introduction of cells capable of regenerating disk tissue may potentially halt or reverse the degeneration associated with IDD. Anabolic and anticatabolic effects and the depth of *in vitro* and animal data are advantages of the cellular supplementation strategy. Yet, the viability of these new cells in the setting of limited cellular nutrition and differentiation signals, and concern whether the extracellular matrix produced by these is similar to native matrix, are acknowledged disadvantages.

Nonetheless, cells from a variety of sources have been explored. Autologous (ie, from the patient) sources include native disk cells and mesenchymal stem cells (MSCs) accumulated from bone marrow. Intuitively, the cells collected from the patient's own degenerated disks are less attractive because they would likely be inherently abnormal and poorly suited to act as an agent of repair. The premise for autologous disk cell transplantation has been established with the use of rat [26] and canine [27,28] models. Autologous human disk cells gathered during therapeutic discectomy have been evaluated, and results from a 2-year prospective, controlled, randomized, multicenter study are promising [28-30]. Obtaining pure nucleus pulposus cells free of other cells (eg, fibroblasts and macrophages), however, is challenging [29,30]. The batches of autologous stem cells obtained from the patient's own bone marrow through density centrifugation and adherence to plastic probably do not contain a high concentration of pure homogenous mesenchymal cells with defined characteristics. Human adipose-derived MSCs are abundant and easy to harvest and have become a focus of interest for application to diskogenic CLBP [31]. Commercially available techniques currently are under development [32].

Therefore, the use of autologous progenitor cells, regardless of their source, calls for an *ex vivo* expansion of the cells after being immunoselected in preparation for implantation—an expensive process [33]. Cell expansion, however, currently is not approved for clinical use outside of the Food and Drug Administration—regulated premarket studies of new technologies. The use of allogeneic (ie, obtained from same species subjects other than the patient) MSCs may be more cost-effective. MSCs are self-renewing, undifferentiated, pluripotent cells with the capacity to differentiate into osteoblasts, chondroblasts, and adipocytes [34-38]. MSCs assume an intervertebral disk-like phenotype after induction by transforming growth

factor- $\beta$ , dexamethasone, and ascorbate [39], allowing the creation of a universal donor line of these cells. Bone marrow [40-42] stromal cells have been the studied most extensively among the available sources of such cells. In animal models, autologous bone marrow MSCs have been shown to survive and replicate 8-48 weeks after transplantation [42-44]. A single injection of MSCs into the degenerate ovine disk nucleus pulposus restored proteoglycan content and disk height 6 months after injection [45]. On the basis of these animal data, a Food and Drug Administration–regulated, phase 2 safety and effectiveness study of a single intradiskal injection of allografted MSCs is underway in humans [46].

This phase 2, randomized, controlled study of allogeneic MSCs injected into a single, mildly degenerate lumbar intervertebral disk has produced preliminary data [47]. At 12 months after injection, 69% (95% confidence interval [95% CI] 53%-86%) of patients treated with MSCs experienced  $\geq 50\%$  reduction in LBP. Conversely, 33% (95% CI 19%-48%) of control patients achieved this end point. Similarly, a greater proportion of patients who received MSCs experienced minimal residual LBP at 12 months compared with controls. Fifty-two percent of the treatment patients (95% CI 34%-70%) and 18% (95% CI 6%-30%) of the control subjects reported low-intensity LBP ( $\leq 2/10$ ) at 12 months after injection. Hence, on statistical grounds the MSC-treated group fared better regarding meaningful reduction of LBP. A large, pivotal phase 3 follow-up study is under development.

Articular chondrocytes are phenotypically similar to disk cells [48]. Juvenile chondrocytes (JCs) maintain an increased capacity to synthesize extra cellular matrix compared with adult cells [49]. Furthermore, JCs lack cell surface markers that trigger immune responses [49]. Thus, culture-expanded JCs may survive transplantation in unrelated recipients.

A 15-subject pilot study of a single intradiskal injection of JCs into diskography proven painful lumbar disks has yielded promising results [49]. At 1 year after injection, the mean numerical pain score and Oswestry Disability Index both decreased significantly. Although primarily only group data were published, 87% (95% CI 78%-96%) of treated subjects experienced a 30% reduction in Oswestry Disability Index scores [49]. On the basis of these early findings, a larger randomized, controlled trial has been launched [24,50].

Allogeneic adult chondrocytes are now being harvested and expanded in the laboratory after immunoselection. Intervertebral disk tissue is procured from adult human donors, which undergoes a multistep process to select, expand, and enrich progenitor cells. These cells are multipotent for mesenchymal lineages capable of exogenous production of proteoglycan and collagen II. Although untested in human subjects, this emerging cell therapy technology has safely improved

disk height and proteoglycan and collagen content in animal models [47]. A phase 1 human clinical trial is being developed.

The survival of the transplanted cells for a sufficient period of time for them to accomplish their intended objective is of peak interest. As discussed, a degenerated disk's interior is acidic, hypoxic, and lacks nutrients. Transplanted cells may need to be prepared to survive within this environment after intradiskal injection, possibly by genetic manipulation, to restore extracellular matrix under these suboptimal conditions.

## Painful Facet and Sacroiliac Joints

### Pathophysiology

The lumbar facet joint (FJ) is a diarthrodial synovial joint encased by an inner synovial membrane and outer joint capsule containing articular and subchondral cartilage, an intra-articular meniscus, and rheological synovial fluid. Nociceptive C-type fibers have been confirmed on both the synovial membrane and joint capsule, and group III high-threshold, slow-conducting mechanosensitive, somatosensory units are present in both the articular and subchondral cartilage [51-54]. It seems sensible therefore that the synovial membrane, joint capsule, and articular and subchondral cartilage can transmit pain.

The progression of the lumbar spine degenerative cascade results in disk desiccation and loss of disk height. Consequently, an escalating compressive load is shifted onto the posterior elements [55], leading to degeneration and increased excitability of the synovial membrane nociceptive nerve fibers, joint capsule, and articular and subchondral cartilage [51-53,56]. In experimental models of osteoarthritis, these articular nerves become hyperalgesic, spontaneously discharge, and are sensitive to non-noxious joint movements [56]. Arthritic lumbar FJs can become symptomatic, leading to pain and disability [5]. A hallmark of osteoarthritis is the imbalance of cartilage and matrix degradation and their synthesis resulting in a catabolic state. Components of the extracellular matrix include proteoglycans comprising glycosaminoglycans attached to a backbone of hyaluronic acid (HA) [57], which provides the viscoelastic quality of synovial fluid affording lubricant and shock absorber functions [58]. The viscoelasticity of the synovial fluid is reduced as the concentration and the molecular weight of intra-articular HA decrease as a result of the arthritic state. As these lubricant properties decrease, destruction of cartilage and bone ensues. Because of its viscoelastic properties, HA protects cells and anatomic structures against mechanical overloading [58,59].

The sacroiliac joint is the largest axial joint in the body and on average has a surface area equal to 17.5 cm<sup>2</sup> [60]. A shear force can contribute to altered

mechanics of the articulating components of the sacroiliac joint [61]. Anatomical studies in cadavers have detected nociceptors within both the joint capsule and in the surrounding ligaments [62]. Furthermore, clinical studies have documented evoking of LBP upon capsular distension performed in asymptomatic volunteers [63-66]. Therefore, the sacroiliac joint is exposed to injurious events and contains nociceptive fibers capable of transmitting pain.

### Treatment

A paucity of work has been completed in which authors have investigated the role of biologic treatments for lumbar facet and sacroiliac joints. Exogenous HA enhances the synthesis of matrix proteins, glycosaminoglycan, and proteoglycans; alters inflammatory mediators [59]; and reduces apoptosis of chondrocytes [67], all of which collectively may promote or spare intra-articular cartilage [59] in painful FJ arthropathy. Exogenous HA may be able to balance the spectrum away from cartilage degradation back towards its synthesis [59].

Successive intra-articular injections of exogenous HA (hylan G-F 20) into painfully arthritic lumbar FJs can reduce LBP, disability, and improve sitting tolerance up to 6 months after treatment. Patient satisfaction improved and oral analgesics reduced similarly during the first 6 months but not during the second 6 months after treatment. The lack of a durable treatment effect could be indicate that the injected exogenous HA achieved some analgesic effect via modulation of the nociceptors within the joint. Although speculative, injecting a smaller volume (0.5 mL) per injection and completing more injections per joint may more successfully reduce LBP over time by stimulation of matrix proteins and chondrocyte proliferation. These pilot data support the pursuit of follow-up, rigorous controlled trials to better determine the effectiveness and safety of viscosupplementation for FJ-mediated LBP. Although this strategy does not involve cellular supplementation, the act of introducing exogenous HA into an arthritic FJ may promote native chondrocyte activity.

Although yet to be tested, the direct injection of stem cells into painful lumbar FJs is supported by the current promising findings of similar techniques for painful arthritic knee joints [68,69] which, similar to FJs, contain cartilage and synovium.

### Conclusion

The most common structural source of adult CLBP is the intervertebral disk. Painful disks suffer from non-healing annular fissures. Emerging intradiskal biologic treatment technologies should address both the annular tear and associated degeneration. Effective intradiskal biologic treatments will need to also improve the

biomechanical performance of the injured intervertebral disk. Otherwise, cells supplemented into this inhospitable environment may not survive over time because of a lack of adequate nutrients and harmful intradiskal pressures. Ultimately, a multipronged approach may prove optimal by combining different technologies, such as tissue scaffolding for 3-dimensional proliferation and lamellar cross-linking; cellular supplementation to produce matrix and reduce inflammation; and growth factors to stimulate the inserted cells. However, given the current state of regulatory constraints, the process for commercializing a product of multiple biologic technologies may be too prohibitive.

### References

- Dillane JB, Fry J, Kalton G. Acute back syndrome: A study from general practice. *Br Med J* 1966;2:82.
- Spratt KF, Lehmann TR, Weinstein JN, et al. A new approach to low back physical examination. Behavioral assessment of mechanical signs. *Spine* 1990;15:96-102.
- Nachemson AL. The natural course of low back pain. In: White AA, ed. American Academy of Orthopedic Surgeons Symposium on Idiopathic Low Back Pain. St Louis, MO: CV Mosby; 1982; 46-51.
- DePalma MJ, Ketchum JM, Trussell BS, Saullo TR, Slipman CW. Does the location of low back pain predict its source? *PM R* 2011;3: 33-39.
- DePalma MJ, Ketchum JM, Saullo T. What is the source of chronic low back pain and does age play a role? *Pain Med* 2011;12:224-233.
- Schwarzer AC, Aprill CN, Derby R, et al. The prevalence and clinical features of internal disc disruption in patients with chronic low back pain. *Spine* 1995;20:1878-1881.
- Moneta GB, Videman T, Kaivanto K, et al. Reported pain during lumbar discography as a function of annular ruptures and disc degeneration. A re-analysis of 833 discograms. *Spine* 1994;19:1968-1974.
- Peng B, Wu W, Hou S, et al. The pathogenesis of discogenic low back pain. *J Bone Jt Surg Br* 2005;87-B(1).
- Maigne JY, Aivaliklis A, Fabrice P. Results of sacroiliac joint double block and value of sacroiliac pain provocation tests in 54 patients with low back pain. *Spine* 1996;21:1889-1892.
- Schwarzer AC, Aprill CN, Bogduk N. The sacroiliac joint in chronic low back pain. *Spine* 1995;20:31-37.
- Coppes MH, Marani E, Thomeer RT, Groen GJ. Innervation of "painful" lumbar discs. *Spine* 1997;22:2342-2350.
- Freemont AJ, Watkins A, Maitre CL, et al. Nerve growth factor expression and innervation of the painful intervertebral disc. *J Pathol* 2002;197:286-292.
- Peng B, Hao J, Hou S, et al. Possible pathogenesis of painful intervertebral disc degeneration. *Spine* 2006;31:560-566.
- Wolfer LR, Derby R, Lee JE, Lee SH. Systematic review of lumbar provocation discography in asymptomatic subjects with a meta-analysis of false-positive rates. *Pain Physician* 2008;11:513-538.
- Walsh T, Weinstein J, et al. The question of discography revisited. A controlled prospective study of normal volunteers to determine the false positive rate. *J Bone Joint Surg Am* 1990;72:1081-1088.
- DePalma MJ, Lee JE, Peterson L, Wolfer L, Ketchum J, Derby R. Are outer annular fissures stimulated during diskography the source of diskogenic low-back pain? An analysis of analgesic diskography data. *Pain Med* 2009;10:488-494.
- Burke JG, Watson RWG, McCormack D, et al. Intervertebral discs which cause low back pain secrete high levels of proinflammatory mediators. *J Bone Joint Surg Br* 2002;84-B:196-201.
- Weiler C, Nerlich AG, Bachmeier BE, et al. Expression and distribution of tumor necrosis factor alpha in human lumbar

- intervertebral discs: A study in surgical specimen and autopsy controls. *Spine* 2004;30:44-54.
19. Brown M, Hukkanen M, McCarthy I, et al. Sensory and sympathetic innervation of the vertebral endplate in patients with degenerative disc disease. *J Bone Joint Surg Br* 1997;79-B:147-153.
  20. Cunha JM, Cunha FQ, Poole S, et al. Cytokine-mediated inflammatory hyperalgesia limited by interleukin-1 receptor antagonist. *Br J Pharmacol* 2000;130:1418-1424.
  21. Handa T, Ishihara H, Ohshima H, et al. Effects of hydrostatic pressure on matrix synthesis and matrix metalloproteinase production in the human lumbar intervertebral disc. *Spine* 1997;22:1085-1091.
  22. Ohshima H, Urban JP, Bergel DH. Effect of static load on matrix synthesis rates in the intervertebral disc measured in-vitro by a new perfusion technique. *J Orthop Res* 1995;13:22-29.
  23. Adams MA, Freeman BJC, Morrison HP, et al. Mechanical initiation of intervertebral disc degeneration. *Spine* 2000;25:1625-1636.
  24. McNally D, Shackelford I, Goodship A, Mulholland R. In vivo stress measurement can predict pain on discography. *Spine* 1996;21:2580-2587.
  25. Gruber HE, Ingram JA, Davis DE, et al. Increased cell senescence is associated with decreased cell proliferation in vivo in the degenerating human annulus. *Spine J* 2009;9:210-215.
  26. Gruber HE, Johnson TL, Leslie K, et al. Autologous intervertebral disc cell implantation: A model using *Psammomys obesus*, the sand rat. *Spine* 2002;27:1626-1633.
  27. Ganey T, Libera J, Moos V, et al. Disc chondrocyte transplantation in a canine model: A treatment for degenerated or damaged intervertebral disc. *Spine* 2003;28:2609-2620.
  28. Ganey TM, Meisel HJ. A potential role for cell-based therapeutics in the treatment of intervertebral disc herniation. *Eur Spine J* 2002;11(Suppl 2):S206-S214.
  29. Meisel HJ, Ganey T, Hutton WC, et al. Clinical experience in cell-based therapeutics: Intervention and outcome. *Eur Spine J* 2006;15(Suppl 3):S397-S405.
  30. Meisel HJ, Siodla V, Ganey T, et al. Clinical experience in cell-based therapeutics: Disc chondrocyte transplantation: A treatment for degenerated or damaged intervertebral disc. *Biomol Eng* 2007;24:5-21.
  31. Gruber HE, Deepe R, Hoelscher GL, et al. Human adipose-derived mesenchymal stem cells: Direction to a phenotype sharing similarities with the disc, gene expression profiling, and coculture with human annulus cells. *Tissue Eng Part A* 2010;6(9):2843-2860.
  32. SpinalCyte. Research. Available at: <http://spinalcyte.com/research>. Accessed February 25, 2015.
  33. Evans C. Potential biologic therapies for the intervertebral disc. *J Bone Joint Surg Am* 2006;88-A:95-98.
  34. Friedenstein AJ, Gorskaja JF, Kulagina NN. Fibroblast precursors in normal and irradiated mouse hematopoietic organs. *Exp Hematol* 1976;4:267-274.
  35. Pittenger MF, Mackay AM, Beck SC, et al. Multilineage potential of adult human mesenchymal stem cells. *Science* 1999;284:143-147.
  36. Deans RJ, Moseley AB. Mesenchymal stem cells: Biology and potential clinical uses. *Exp Hematol* 2000;28:875-884.
  37. Baksh D, Song L, Tuan RS. Adult mesenchymal stem cells: Characterization, differentiation, and application in cell and gene therapy. *J Cell Mol Med* 2004;8:301-316.
  38. Lin Z, Willers C, Xu J, et al. The chondrocyte: Biology and clinical application. *Tissue Eng* 2006;12:1971-1984.
  39. Steck E, Bertram H, Abel R, et al. Induction of intervertebral disc-like cells from adult mesenchymal stem cells. *Stem Cells* 2005;23:403-411.
  40. Song H, Kwon K, Lim S, et al. Transfection of mesenchymal stem cells with the FGF-2 gene improves their survival under hypoxic conditions. *Mol Cells* 2005;19:402-407.
  41. Zhang YG, Guo X, Xu P, et al. Bone mesenchymal stem cells transplanted into rabbit intervertebral discs can increase proteoglycans. *Clin Orthop Relat Res* 2005;430:219-226.
  42. Sakai D, Mochida J, Iwashina T, et al. Differentiation of mesenchymal stem cells transplanted to a rabbit degenerative disc model: Potential and limitations for stem cell therapy in disc regeneration. *Spine* 2005;30:2379-2387.
  43. Sakai D, Mochida J, Iwashina T, et al. Regenerative effects of transplanting mesenchymal stem cells embedded in atelocollagen to the degenerated intervertebral disc. *Biomaterials* 2006;27:335-345.
  44. Sheikh H, Zakharian K, DeLaTorre RP, et al. In vivo intervertebral disc regeneration using stem cell-derived chondroprogenitors. *J Neurosurg Spine* 2009;10:265-272.
  45. Ghosh P, Shimmon S, Wu J, Ghosh IP, Moore R, Zannettino ACW, Gronthos S, Itescu S. STRO-3+ Immunoselected allogeneic mesenchymal progenitor cells injected into degenerate intervertebral discs reconstitute the proteoglycans of the nucleus pulposus-an experimental study in sheep. Annual Meeting of the Orthopaedic Research Society, Long Beach, CA, 2011.
  46. ClinicalTrials.gov. Safety and Preliminary Efficacy Study of Mesenchymal Precursor Cells (MPCs) in Subjects with Lumbar Back Pain. Available at: <http://www.clinicaltrials.gov/ct2/show/NCT01290367?term=mesoblast&rank=2>. Accessed February 25, 2015.
  47. DePalma M. International Spine Intervention Society, Annual Scientific Meeting, July, 2014, Orlando, FL.
  48. Brittberg M, Lindahl A, Nilsson A, et al. Treatment of deep cartilage defects in the knee with autologous chondrocyte transplantation. *N Engl J Med* 1994;331:889-895.
  49. Coric D, Pettine K, Sumich A, Boltes MO. Prospective study of disc repair with allogeneic chondrocytes. *J Neurosurg Spine* 2013;18:85-95.
  50. A Study Comparing the Safety and Effectiveness of Cartilage Cell Injected Into the Lumbar Disc as Compared to a Placebo. <http://www.clinicaltrials.gov/ct2/show/NCT01771471?term=ISTO&rank=4>. Accessed February 25, 2015.
  51. Marks RC, Houston T, Thulbourne T. Facet joint injection and facet nerve block: A randomized comparison in 86 patients with chronic low back pain. *Pain* 1992;49:325-328.
  52. Ashtar IK, Ashton BA, Gibson SJ, Polak JM, Jaffray DC, Eisenstein SM. Morphological basis for back pain: The demonstration of nerve fibers and neuropeptides in the lumbar facet joint capsule but not in ligamentum flavum. *J Orthop Res* 1992;10:72-78.
  53. Yamashita T, Cavanaugh JM, el-Bohy AA, Getchell TV, King AI. Mechanosensitive afferent units in the lumbar facet joint. *J Bone Joint Surg Am* 1990;72:865-870.
  54. Yamashita T, Cavanaugh JM, Ozaktay AC, Avramov AI, Getchell TV, King AI. Effect of substance P on mechanosensitive units of tissues around facet joint. *J Orthop Res* 1993;11:205-214.
  55. Kirkaldy-Willis WH. The pathology and pathogenesis of low back pain. In: Kirkaldy-Willis WH, ed. *Managing Low Back Pain*. New York, NY: Churchill Livingstone; 1988; 49.
  56. Pozo MA, Balazs EA, Belmonte C. Reduction of sensory responses to passive movements of inflamed knee joints by hylan, a hyaluronan derivative. *Exp Brain Res* 1997;116:3-9.
  57. Bland JH, Cooper SM. Osteoarthritis: A review of the cell biology involved and the evidence of reversibility. Management rationally related to known genesis of pathophysiology. *Semin Arthritis Rheum* 1984;14:106-133.
  58. Schmidt TA, Gastelum NS, Nguyen QT, et al. Boundary lubrication of articular cartilage: role of synovial fluid constituents. *Arthritis Rheum* 2007;56:882-891.
  59. Moreland LW. Intra-articular hyaluronan (hyaluronic acid) and hylans for the treatment of osteoarthritis: Mechanism of action. *Arthritis Res Ther* 2003;5:54-67.
  60. Bernard TN, Cassidy JD. The sacroiliac syndrome. Pathophysiology, diagnosis and management. In: Frymoyer JW, ed. *The Adult Spine: Principles and Practice*. New York, NY: Raven; 1991; 2107-2130.
  61. Sakamoto N, Yamashita T, Takebayashi T, et al. An electrophysiologic study of mechanoreceptors in the sacroiliac joint and adjacent tissues. *Spine* 2001;26:E468-71.

62. Szadek KM, van der Wurff P, van Tulder MW, Zuurmond WW, Perez RR. Diagnostic validity of criteria for sacroiliac joint pain: A systematic review. *J Pain* 2009;10:354-368.
63. Fortin JD, Aprill CN, Ponthieux B, Pier J. Sacroiliac joint: Pain referral maps upon applying a new injection/arthrography technique. Part II: Clinical evaluation. *Spine* 1994;19:1483-1489.
64. Fortin JD, Dwyer AP, West S, Pier J. Sacroiliac joint: Pain referral maps upon applying a new injection/arthrography technique. Part I: Asymptomatic volunteers. *Spine* 1994;19:1475-1482.
65. Dreyfuss P, Snyder BD, Park K, Willard F, Carreiro J, Bogduk N. The ability of single site, single depth sacral lateral branch blocks to anesthetize the sacroiliac joint complex. *Pain Med* 2008;9:844-850.
66. Dreyfuss P, Michaelsen M, Pauza K, et al. The value of medical history and physical examination in diagnosing sacroiliac joint pain. *Spine* 1996;21:2594-2602.
67. Díaz-Gallego L, Prieto JG, Coronel P, et al. Apoptosis and nitric oxide in an experimental model of osteoarthritis in rabbit after hyaluronic acid treatment. *J Orthop Res* 2005;23:1370-1376.
68. Rayegani SM, Raeissadat SA, Taheri MS, et al. Does intra articular platelet rich plasma injection improve function, pain and quality of life in patients with osteoarthritis of the knee? A randomized clinical trial. *Orthop Rev (Pavia)* 2014;18:5405.
69. Orth P, Rey-Rico A, Venkatesan JK, Madry H, Cucciarini M. Current perspectives in stem cell research for knee cartilage repair. *Stem Cells Cloning* 2014;7:1-17.

---

## Disclosure

M.J.D. Virginia iSpine Physicians, PC, 9020 Stony Point Pkwy, Ste 140, Richmond, VA 23235. Address correspondence to: M.J.D.; e-mail: [depalmamj8@yahoo.com](mailto:depalmamj8@yahoo.com)  
Disclosures outside this publication: board membership, ISIS (money to author - expenses reimbursement for travel to BOG meetings); consultancy, Verti, Medtronic, Mesoblast, Kimberly Clark (money to institution); expert testimony (money to institution)

J.J.G. Virginia iSpine Physicians, Richmond, VA  
Disclosure outside this publication: consultancy, Mesoblast

Submitted for publication November 8, 2014; accepted January 23, 2015.

---